Recon: GSK pays $500M upfront to Hengrui for rights to several drugs; PE firms offer $3B to buy Bavarian Nordic
ReconJason Scott
Biologics/ biosimilars/ vaccinesEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyUnited States